US Stocks

Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals develops and sells precision medicines for cancer patients with genetic markers. Their Phase II clinical trial candidate DAY101 aims to treat pediatric patients with relapsed/progressive low-grade glioma using an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor. Additionally, they are working on Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2.